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driving a motor vehicle. In addition, patients with this
potentially reversible condition often perform poorly in the
work situation and experience negative changes to family
relationships. A failure to treat this condition is likely to have
major medical and social consequences.
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Evaluation of the World
Health Organisation'
antibody-testing strategy
for the individual patient
diagnosis of HIV infection
(strategy Ill)
D. J. Martin, N. K. Blackburn, K. F. O'Connell,
E. T. Brant, E. A. Goetsch
Objective. To evaluate the World Health Organisation
(WHO) antibody testing strategy for the individual patient
diagnosis of HIV infection (strategy Ill).
Design. Evaluation of a combination of enzyme-linked
immunosorbent assays (ELlSAs) for the detection of
antibodies to HIV-1 and HIV-2 infection. The WHO strategy
III calls for a combination of three ELlSAs, based on
different antigens and/or differing test principles, to be
used in a sequential fashion. The first part of the study
evaluated various kits as part of a selection process. The
second part of the study was an assessment of the three-
ELlSA testing strategy on routine sera submitted to the
National Institute for Virology (NIV) for HIV testing. In all
instances, the conventional testing protocol, which utilises
a screening ELlSA followed by a confirmatory Western
blot (WB) on positive specimens, was used as the 'gold
standard'.
Setting. The HIV-testing laboratory at the NIV,
Johannesburg.
Results. In the first part of the study, all of the ELlSA kits
evaluated showed high sensitivity and specificity, and a
selection of the kits for part two of the study was made in
accordance with the WHO recommendation. The kits
selected, in order of use, were the Biotest anti-HIV 1/2
(test 1), Pasteur Genelavia Mixt HIV-1/2 (test 2) and Murex
Wellcozyme HIV-1 competitive assay (test 3). This
combination was evaluated using 7 812 sera submitted to
the NIV for serology testing. The sensitivities of the tests
were highly satisfactory (99,6 - 100%) as' were the
specificities (99,2 - 100%). The positive predictive value of
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strategy III at various seroprevalences (0,5 - 25,5%) was
;;. 99,6%. The rate of WB usage when compared with the
previous HIV testing protocol was low (4,6%).
Conclusions. The results of this study suggest that this
testing protocol could be introduced in South Africa with
considerable cost-saving and no reduction in specificity.
S Afr Med J 1995; 85: 877-880.
The National Institute for Virology (NIV)'s conventional
algorithm for testing serum for antibodies to HIV has been to
use an enzyme-linked immunosorbent assay (EllSA) as a
screening test; all negative results were accepted; but sera
found to be repeatedly reactive on ELlSA were retested by a
confirmatory test, usually Western blot (WB). WB has
limitations which include high costs, difficulties in
interpretation and indeterminate reactions.' Recent
technological advances have produced tests which, either
alone or in combination, provide results as accurate as
those obtained with WB.' To maximise accuracy and
minimise cost, the Global Programme on AIDS (GPA) of the
World Health Organisation has recommended strategies for
the laboratory testing of HIV infection.' The selection of the
most appropriate combination of laboratory tests depends
on the following: (I) the objective of HIV testing in the
population concerned (safety of blood or organ donation,
surveillance, individual patient diagnosis); (iI) the sensitivity
and specificity of the laboratory tests used; Vii) the
prevalence of HIV infections in the population tested; and -
vv) the operational characteristics of the tests, including the
cost.
The NIV decided to evaluate the strategy applied to
individual patient diagnosis as outlined in the WHO's
strategy Ill' and compare the results to those of the
conventional testing protocol; confirmatory WB test was
used as the 'gold' standard.
Materials and methods
Selection of antibody tests for strategy 11/
Strategy III calls for the use of three ELlSAs. The tests should
be based on differing test principles, e.g. indirect and
competitive ELlSAs,-and/or have different sources of antigen,
e.g. recombinant antigens and synthetic peptides. The first
test should have a high sensitivity, whereas the subsequent
tests should have high specificities. Although the sensitivity
and specificity values for individual manufacturers' kits were
available and had been recorded in previous evaluations,' we
felt it important to evaluate certain kits in our laboratory.
Evaluation of commercial EL/SA kits
Four commercial ELlSAs were initially selected for the .
evaluation: (I) Wellcozyme HIV 1 + 2 enzyme immunoassay
(EIA) (Murex Diagnostics Ltd, England) based on
recombinant HIV-1 antigens and HIV-2 synthetic peptide;
(iI) Abbott recombinant HIV-1iHIV-2 third-generation EIA
(Abbott Diagnostic Division, Germany); (iil) Genelavia Mixt
HIV-1 and HIV-2 EIA (Sanofi Diagnostics Pasteur, France)
incorporating recombinant and synthetic peptide HIV-1
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antigens and an HIV-2 synthetic peptide antigen; and
(iv) Biotest anti-HIV-1/2 EIA (Biotest AG, Germany) based on
recombinant antigens.
Antigen detection
Abbott HIV AG-1 Monoclonal Kit (Abbott Diagnostic
Division, Germany) was used for the detection of HIV-1 p24
antigen. This was used as a supplementary test for sera
which gave discrepant results (reactive with at least one
ELlSA and negative with at least one ELlSA).
Western blot
All reactive sera were tested by means of the NEW LAV-
BLOT 1 Kit (Sanofi Diagnostics Pasteur, France), which was
used as a confirmatory test. The WHO criteria for positivity
of the WB were adopted (2 of 3 envelope bands gp~1,
gp120, gp160). In addition, for the purposes ofthe.study,
the presence of a single envelope band, gp160, was
considered positive as we felt that it was probably evidence
of early seroconversion. !
Serum specimens
These were sera that were submitted to the NIV for routine
HIV-antibody testing.
Results
The results of this preliminary evaluation, using sera of
unknown HIV-antibody status, are detailed in Table I. They
suggest that all the ELlSAs had high sensitivity and
specificity; the selection of the three ELlSAs for the use in
strategy III was determined by the need for tests with
differing test principles (fable 11). This decision was made in
accordance with the WHO recommendations. The Biotest
assay, whose sensitivity in our study confirmed previously
published results,' was selected as the first-line screening
test, followed by the Pasteur Genelavia Mixt EIA. The third
test selected, which was not included in the initial panel,
was the Murex Wellcozyme HIV-1 competitive assay. The
Wellcozyme HIV-1 assay was specifically selected to detect
HIV-1 and was pretested against a well-characterised
'in-house' HIV-1 antibody panel which showed a 100%
correlation. The Abbott HIV-1/HIV-2 third-generation test
gave results equivalent to those of the Wellcozyme HIV-1
and 2 EIA tests, but was not considered for the study
because of the relatively large quantity of specimens
required (150 Ill) in the tes~ protocol. The sensitivities of the
three selected ELlSAs were further assessed with a
seroconversion panel (Boston Biomedica Inc. panel-G) with
satisfactory results. The Biotest EIA was found to be the
most sensitive (detailed results not shown).
Evaluation of strategy III
The WHO recommendations state that serum that is non-
reactive in the first test is to be considered HIV antibody-
negative, as is serum that is reactive in the first test but
non-reactive in the second. Serum reactive in all three tests
is considered HIV antibody-positive. Serum that is reactive in
the first and second tests, but non-reactive in the third test, is




Table I. Results of a series of two EIA systems tested in parallel against routine serum specimens
Abbott EIA (A) and Murex HIV 1/2 EIA (M) tested against 704 sera True positive 113 True negative 591
A+M A only M only A M
ELlSA +ve 116 0 0 Sensitivity 100 100
WB+ve 110 Specificity 99,5 99,5
gp160 band only 3 +ve PV* 97,4 97,4
Not confirmed 3 -ve PV 100 100
Pasteur EIA (P) and Murex HIV 1/2 EIA (M) tested against 1 483 sera True positive 200 True negative 1 283
P+M P only M only P M
ELlSA +ve 199 6 4 Sensitivity 100 99,5
WB +ve 194 0 0 Specificity 99,5 99,7
gp160 band 5 1 0 +ve PV 97,6 98
Not confirmed 0 5 4 -ve PV 100 99,9
Pasteur EIA (P) and Biotest EIA (B) tested against 1 041 sera True positive 190 True negative 851
P+B P only B only P B
ELlSA +Ve 190 4 4 Sensitivity 99,5 100
WB +ve 187 0 1(p24 Ag) Specificity 99,4 99,5
gp160 band 1 0 0 +ve PV 97,4 97,9
p24Ag 0 0 1 -ve PV 99,9 100
HIV-2 1 0 0
Not confirmed 1 4 3
PV ; Predictive value.
True positive
Sensitivity; --------
True positive + false negative
True negative
Specificity ; --------
True negative + false positive
True positive
Positive predictive value; --------
True positive + false positive
True negative
Negative predictive value; --------
True negative + false negative
Table Ill. Results of 7 812 sera tested using the WHO strategy III
EIA system
Sensitivity and specificity of the"3 ELlSAs when tested sequentially
Biotest Pasteur Murex
Table 11. Characteristics of selected tests
ELlSA Manufacturer Antigens Test principle
1 Biotest Recombinant Indirect
HIV-1/HIV-2 assay
2 Pasteur Recombinant Indirect
HIV-1 + synthetic assay
peptides HIV-1/HIV-2
3 Murex Recombinant HIV-1 Competitive
Wellcozyme assay
The samples tested by means of strategy III were 7 812
sera routinely submitted for HIV serology testing. In the
event of a discrepant result being obtained (reactive with at
least one ELlSA and negative with at least one), the serum
was further tested by WB and for p24 antigen. Sera that
were non-reactive on the third ELlSA were tested for HIV-2
using the LAV-BLOT 2 (Sanofi Diagnostics Pasteur, France).
Results
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Discussion
The WHO strategy for HIV testing provides an opportunity
for developing countries to adopt HIV testing protocols that
maximise accuracy and minimise cost. Inherent in this
strategy is the replacement of the WB with a combination of
ELlSAs that utilise different antigens and have differing test
principles. Although combinations of immunoassays have
been evaluated before,H it was deemed essential to
evaluate the strategy in the local situation, with sera
obtained from the local population. This is of major
importance in Africa where serological assays have
demonstrated lower sensitivity and specificity.'-"
The sensitivity and specificity of the tests used.in strategy
III showed values that were highly satisfactory (Table Ill).
Although the prevalence of HIV infection in the sera tested
was relatively high - 1 185 positive out of 7 812 (15,2%) -
the sera included cohorts whose seroprevalence varied from
0,5% to 25,5%. The positive predictive value (PPV) of
strategy III at various seroprevalences within this range was
;;, 99,6% and is in accordance with previously published
work.9 The high sensitivity of the Biotest screening test,
demonstrated in previously published results; was
confirmed in our study. This test, however, had a high rate of
false positives (0,6%).
In the WHO strategy Ill, which is recommended for the
identification of asymptomatic HIV-infected individuals, sera
that produce equivocal ELlSA results should be retested. If
they are repeatedly equivocal, WB testing may be
considered, especially in populations that have a low HIV
prevalence « 1%). In addition, a second specimen of serum
should be obtained and retested after a period of 2 weeks.
Similarly, discrepant results from the first and second
ELlSAs should not be reported as negative, as is
recommended by the WHO strategy, but should be reported
as probably negative. These may be cases of early
seroconversion. A second serum sample should be
requested and retested after a period of 2 weeks. One case
of seroconversion in our series was identified by means of a
follow-up blood specimen. Discrepant results obtained from
the third ELlSA in our protocol may indicate infection with
HIV-2, and are the reason why an ELlSA to detect infection
with HIV-1 only was included. Clearly, further testing with
appropriate WB for HIV-2 and HIV-1 will help identification.
It is clear from the results of our study that the
replacement of the WB with WHO strategy III is to be
welcomed. WB tests can produce relatively high rates of
false-positive or indeterminate results.,a The added
disadvantages of WB tests are its technical demands and
the cost. In this study, the rate of WB usage (4,6%) was low
compared with our laboratory's previous protocol.
Quite clearly, there is a considerable cost-saving in
employing strategy Ill. It has previously been shown that at
very low prevalences of HIV, where only a relatively small
number of all sera are positive (both true positives and false
positives), there is little saving in. cost. With increasing
prevalences there is increased cost-saving9 which was
confirmed in the present study. Estimation of costs related
to the use of the individual kits showed that, when dealing
with reactive specimens, the 3 ELlSA-based strategies
would result in an 80% saving in cost, compared with an
ELlSAlWB strategy. Quite clearly, this figure will vary from
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laboratory to laboratory according to the choice of individual
kits, the particular setting of the laboratory and the
throughput of specimens in the system. Nonetheless, a
considerable saving in cost will be achieved. Worldwide,
laboratory testing accounts for approximately 65% of
expenditure of national AIDS programmes." In the
developing world, where resources are limited, this saving in
cost can be utilised to strengthen other facets of national
AIDS programmes. In addition, the saving in 'emotional'
costs associated with indeterminate WB results will be
obviated. Indeterminate WB results frequently necessitate
repeated follow-up testing. ~
Recently a HIV variant, the so-called subtype 0, was'
described in West Africa'2." and France.'· The genetic
composition of this variant differs significantly from the
previously described HIV-1 and HIV-2 subtypes. Certain HIV
ELlSA testing kits failed to detect antibodies in indivjduals
infected with subtype 0." The prevalence of this v~rfant in
South Africa is unknown. However, after scrutiny of the
testing panels," it was noteworthy that the combination of
tests chosen in our protocol would not have missecf
antibodies to subtype O.
Implementation of the WHO strategy III testing protocol
for individual patient diagnosis will result in large cost and
labour savings, which would substantially improve the
efficiency of our national AIDS programme.
It is not the intention of the authors to recommend or
endorse any particular manufacturers' kits. The kits chosen
fulfilled the basic criteria of strategy Ill.
We would like to thank Dr S. Lyons for the p24 antigen assays,
Mrs J. Winfield for technical assistance and Dr B. \7an Niekerk for
helpful advice. In addition, our sincere thanks to Mrs J. Perks for
the preparation of the manuscript.
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